LKB1 signaling is altered in skeletal muscle of a Duchenne muscular dystrophy mouse model
Disease Models & Mechanisms · 2023
DOI: 10.1242/dmm.049930 ↗Kurz gefasst
Fachartikel in der Zeitschrift Disease Models & Mechanisms, 2023. Verfasst von Brigida Boccanegra und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy-Drug Sciences, University of Bari 'Aldo Moro', 70125 Bari, Italy. Hauptthemen laut MEDLINE: AMP-Activated Protein Kinases, Muscular Dystrophy, Duchenne. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dell'Università e della Ricerca, Duchenne Parent Project, Fondazione CON IL SUD.
Abstract (Originalsprache)
The potential role of liver kinase B1 (LKB1) in the altered activation of the master metabolic and epigenetic regulator adenosine monophosphate-activated protein kinase (AMPK) in Duchenne muscular dystrophy has not been investigated so far. Hence, we analyzed both gene and protein levels of LKB1 and its related targets in gastrocnemius muscles of adult C57BL/10 mdx mice and D2 mdx mice, a model with a more severe dystrophic phenotype, as well as the sensitivity of the LKB1–AMPK pathway to AMPK activators, such as chronic exercise. Our data show, for the first time, a reduction in the levels of LKB1 and accessory proteins, MO25 and STRADα, in both mdx strains versus the respective wild type, which was further impaired by exercise, in parallel with a lack of further phosphorylation of AMPK. The AMPK-like kinase salt-inducible kinase (SIK) and class II histone deacetylases, along with expression of the HDAC target gene Mef2c, were also altered, supporting an impairment of LKB1-SIK-class II histone deacetylase signaling. Our results demonstrate that LKB1 may be involved in dystrophic progression, paving the way for future preclinical studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy-Drug Sciences, University of Bari 'Aldo Moro', 70125 Bari, Italy.
- Preclinical R&D Department, Italfarmaco S.p.A., Cinisello Balsamo, 20092 Milan, Italy.
ORCID-Profile: Brigida Boccanegra, Paola Mantuano, Elena Conte, Ornella Cappellari, Gianluca Fossati, Christian Steinkühler, Annamaria De Luca
Förderung
- Ministero dell'Università e della Ricerca
- Duchenne Parent Project
- Fondazione CON IL SUD
- Ministero dell’Istruzione, dell’Università e della Ricerca
Zitieren
APA
Boccanegra, B., Mantuano, P., Conte, E., Cerchiara, A. G., Tulimiero, L., Quarta, R., Caputo, E., Sanarica, F., Forino, M., Spadotto, V., Cappellari, O., Fossati, G., Steinkühler, C., & De Luca, A. (2023). LKB1 signaling is altered in skeletal muscle of a Duchenne muscular dystrophy mouse model. Disease Models & Mechanisms. https://doi.org/10.1242/dmm.049930
Vancouver
Boccanegra B, Mantuano P, Conte E, Cerchiara AG, Tulimiero L, Quarta R, et al. LKB1 signaling is altered in skeletal muscle of a Duchenne muscular dystrophy mouse model. Disease Models & Mechanisms. 2023. doi:10.1242/dmm.049930
BibTeX
@article{Boccanegra2023,
author = {Boccanegra, Brigida and Mantuano, Paola and Conte, Elena and Cerchiara, Alessandro Giovanni and Tulimiero, Lisamaura and Quarta, Raffaella and Caputo, Erika and Sanarica, Francesca and Forino, Monica and Spadotto, Valeria and Cappellari, Ornella and Fossati, Gianluca and Steinkühler, Christian and De Luca, Annamaria},
title = {LKB1 signaling is altered in skeletal muscle of a Duchenne muscular dystrophy mouse model},
journal = {Disease Models & Mechanisms},
year = {2023},
doi = {10.1242/dmm.049930}
}
EUVIMED